Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,848,415 papers from all fields of science
Search
Sign In
Create Free Account
MK-7965
Known as:
CDK inhibitor SCH 727965
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
dinaciclib
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
Zhenghu Chen
,
Zhenyu Wang
,
+10 authors
Jianhua Yang
Scientific reports
2016
Corpus ID: 11030496
Neuroblastoma (NB), the most common extracranial solid tumor of childhood, is responsible for approximately 15% of cancer-related…
Expand
2015
2015
Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models
Chaoxin Hu
,
Tikva Dadon
,
+7 authors
A. Maitra
Molecular Cancer Therapeutics
2015
Corpus ID: 29763
KRAS is activated by mutation in the vast majority of cases of pancreatic cancer; unfortunately, therapeutic attempts to inhibit…
Expand
Highly Cited
2014
Highly Cited
2014
Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.
M. Mita
,
A. Joy
,
+9 authors
C. Shapiro
Clinical breast cancer
2014
Corpus ID: 32600420
Highly Cited
2014
Highly Cited
2014
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.
J. Stephenson
,
J. Nemunaitis
,
+10 authors
M. Edelman
Lung cancer
2014
Corpus ID: 22859827
Review
2014
Review
2014
Dinaciclib for the treatment of breast cancer
C. Criscitiello
,
G. Viale
,
A. Esposito
,
G. Curigliano
Expert opinion on investigational drugs
2014
Corpus ID: 28744904
Introduction: Cyclin-dependent kinases (CDK) represent attractive targets in oncology due to their key role in controlling gene…
Expand
2013
2013
andomized phase 2 study of the cyclin-dependent kinase inhibitor inaciclib ( MK-7965 ) versus erlotinib in patients with non-small cell ung cancer
J. Stephensona
,
John Nemunaitisb
,
+9 authors
Martin J. Edelmane
2013
Corpus ID: 46988083
Objectives: Dinaciclib (MK-7965, formerly SCH 727965), a novel, small-molecule inhibitor of cyclindependent kinases, has been…
Expand
Highly Cited
2012
Highly Cited
2012
Cyclin-dependent kinase inhibitors move into Phase III
Malini Guha
Nature Reviews Drug Discovery
2012
Corpus ID: 34625364
After more than a decade of clinical development for cancer and numerous failures, Phase III trials of cyclin-dependent kinase…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE